Investors

Developing transformative therapies targeting cancer

Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.

Recent News
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress More
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer More
Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares More
Events


Copyright West LLC. Minimum 15 minutes delayed.